Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 21, 2009, Pages 8760-8765

  Guma, Monica ^a   Rius, Jordi ^a   Duong Polk, Karen X ^b   Haddad, Gabriel G ^c   Lindsey, James D ^b   Karin, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Neoangiogenesis; Retinopathy of prematurity

Indexed keywords

STRESS ACTIVATED PROTEIN KINASE 1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROLENTAL FIBROPLASIA;

ANIMALS; ANOXIA; CELL LINE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 8; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; RETINAL DISEASES; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE; MUS;

EID: 66649129868     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0902659106     Document Type: Article

References (48)

1. Fleck BW, McIntosh N (2008) Pathogenesis of retinopathy of prematurity and possible preventive strategies. Early Hum Dev 84:83-88.
2. Chen J, Smith LE (2007) Retinopathy of prematurity. Angiogenesis 10:133-140. (Pubitemid 46440629)
3. Andreoli CM, Miller JW (2007) Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18:502-508.
4. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974. (Pubitemid 43093963)
5. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M (2007) Ocular neovascularization: Basic mechanisms and therapeutic advances. Surv Ophthalmol 52(Suppl 1):S3-S19. (Pubitemid 46107520)
6. Young TL, et al. (1997) Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J Aapos 1:105-110. (Pubitemid 127701623)
7. Alon T, et al. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024-1028.
8. Kusaka S, et al. (2008) Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: A pilot study. Br J Ophthalmol 92:1450-1455.
9. Mason JO, 3rd, Nixon PA, White MF (2006) Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 142:685-688.
10. Takeda AL, Colquitt J, Clegg AJ, Jones J (2007) Pegaptanib and ranibizumab for neovascular age-related macular degeneration: A systematic review. Br J Ophthalmol 91:1177-1182. (Pubitemid 47344893)
11. Karin M, Gallagher E (2005) From JNK to pay dirt: Jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 57:283-295. (Pubitemid 40904256)
12. Pages G, et al. (2000) Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 275:26484-26491.
13. Smith LE, et al. (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Visual Sci 35:101-111. (Pubitemid 24046832)
14. Stone J, et al. (1996) Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Visual Sci 37:290-299. (Pubitemid 26057055)
15. Pierce EA, et al. (1995) Vascular endothelialgrowthfactor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 92:905-909.
16. Gardiner TA, et al. (2005) Inhibition of tumor necrosis factor-α improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol 166:637-644. (Pubitemid 40189058)
17. Behrens A, Sibilia M, Wagner EF (1999) Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet 21:326-329. (Pubitemid 29124945)
18. Hreniuk D, et al. (2001) Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/ reoxygenation in rat cardiac myocytes. Mol Pharmacol 59:867-874. (Pubitemid 32274016)
19. Naug HL, Browning J, Gole GA, Gobe G (2000) Vitreal macrophages express vascular endothelial growth factor in oxygen-induced retinopathy. Clin Exp Ophthalmol 28:48-52. (Pubitemid 30433252)
20. Ishibashi T, et al. (1997) Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 235:159-167. (Pubitemid 27129479)
21. Borsello T, et al. (2003) A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 9:1180-1186. (Pubitemid 37173703)
22. Kaneto H, et al. (2004) Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 10:1128-1132. (Pubitemid 39424876)
23. Hui L, et al. (2008) Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 down-regulation. J Clin Invest 118:3943-3953.
24. Minet E, et al. (2001) c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp Cell Res 265:114-124. (Pubitemid 32989069)
25. Le YJ, Corry PM (1999) Hypoxia-induced bFGF gene expression is mediated through the JNK signal transduction pathway. Mol Cell Biochem 202:1-8. (Pubitemid 30099732)
26. Chandel NS, et al. (1998) Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 95:11715-11720. (Pubitemid 28460480)
27. Kamata H, et al. (2005) Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120:649-661. (Pubitemid 40343077)
28. Forsythe JA, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604-4613. (Pubitemid 26272112)
29. Oosthuyse B, et al. (2001) Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 28:131-138. (Pubitemid 32538057)
30. Kaelin WG, Ratcliffe PJ (2008) Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell 30:393-402.
31. Rius J, et al. (2008) NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 453:807-811.
32. Pages G, Pouyssegur J (2005) Transcriptional regulation of the vascular endothelial growth factor gene: A concert of activating factors. Cardiovasc Res 65:564-573. (Pubitemid 40138977)
33. Schmidt D, et al. (2007) Critical role for NF-κB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J 26:710-719. (Pubitemid 46253848)
34. Kallunki T, Deng T, Hibi M, Karin M (1996) c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 87:929-939. (Pubitemid 26404291)
35. Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4:E131-E136. (Pubitemid 34521026)
36. Smeal T, et al. (1991) Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature 354:494-496. (Pubitemid 21896867)
37. Zachary I (2005) Neuroprotective role of vascular endothelial growth factor: Signalling mechanisms, biological function, and therapeutic potential. Neurosignals 14:207-221. (Pubitemid 41661355)
38. Carmeliet P, et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439. (Pubitemid 26102719)
39. Ferrara N, et al. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442. (Pubitemid 26102720)
40. Ema M, et al. (1997) A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94:4273-4278. (Pubitemid 27194231)
41. Vinores SA, et al. (2006) Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 206:749-758. (Pubitemid 43191050)
42. Jiang J, et al. (2009) Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1α and VEGF. J Cell Physiol 218:66-74.
43. Kim JH, et al. (2008) Absence of intravitreal bevacizumab-induced neuronal toxicity in the retina. Neurotoxicology 29:1131-1135.
44. Inan UU, et al. (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Visual Sci 48:1773-1781.
45. Dafer RM, Schneck M, Friberg TR, Jay WM (2007) Intravitreal ranibizumab and bevacizumab: A review of risk. Semin Ophthalmol 22:201-204. (Pubitemid 47346972)
46. Ferrandi C, et al. (2004) Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats. Br J Pharmacol 142:953-960. (Pubitemid 39037045)
47. Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437:497-504. (Pubitemid 41613541)
48. Banin E, et al. (2006) T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Visual Sci 47:2125-2134. (Pubitemid 46768297)